EX-10.7



 Exhibit 10.7 
 INSYS THERAPEUTICS, INC. 

AMENDED AND RESTATED 
 EMPLOYMENT AGREEMENT 
 This Amended
and Restated Employment Agreement (“Agreement”) is entered into as of the 18th day of April, 2013 (the “Effective Date”), by and between Dr. Larry Dillaha (“Executive”) and Insys Therapeutics, Inc. (the
“Company”). 
 RECITALS 

WHEREAS, the Company desires to continue to employ Executive pursuant to the terms, provisions and
conditions set forth in this Agreement; and 
 WHEREAS, Executive desires to accept and
continue his employment on the terms, provisions and conditions set forth in this Agreement. 

NOW, THEREFORE, in consideration of the mutual promises and covenants contained
herein, the Company and Executive agree as follows: 
 AGREEMENT 

In consideration of the foregoing Recitals and the mutual promises and covenants herein contained, and for other good and
valuable consideration, the parties agree as follows: 
 1.
      EMPLOYMENT BY THE COMPANY. 
 1.1       Position.    Subject to the terms set forth herein, the Company hereby employs Executive in the position of Chief Medical Officer and
Executive hereby accepts such employment. During Executive’s employment by the Company, Executive shall devote Executive’s full business energies, interest, abilities and productive time to the proper and efficient performance of
Executive’s duties under this Agreement. 
 1.2       Duties and
Location.    Executive shall have the title of Chief Medical Officer and shall report to the Company’s Chief Executive Officer (“CEO”). Executive shall do and perform all services, acts or things
necessary or advisable which are normally associated with the position of Chief Medical Officer, as required by the CEO. Executive shall work at the Company’s facility in Chandler, Arizona, provided that the Company may from time to time
require Executive to travel temporarily to other locations in connection with the Company’s business. 

1.3       Policies and Procedures.    The employment
relationship between the parties shall be governed by this Agreement and by the policies and practices established by the Company and/or the Company’s Board of Directors (the “Board”). In the event that the terms of this
Agreement differ from or are in conflict with the Company’s policies or practices, this Agreement shall control. 
 1.4       Exclusive
Employment.    Except with the prior written consent of the Board, Executive will not during employment with the Company undertake or engage in any other employment, occupation or business enterprise, other than ones in which
Executive is a passive investor. 

  
 1 








 1.5     Agreement not to Participate in
Company’s Competitors.    During Executive’s employment with the Company, Executive agrees not to acquire, assume or participate in, directly or indirectly, any position, investment or interest known by Executive to
be adverse or antagonistic to the Company, its business, or prospects, financial or otherwise, or in any company, person, or entity that is, directly or indirectly, in competition with the business of the Company or any of its Affiliates (as defined
below). Ownership by Executive, in professionally managed funds over which the Executive does not have control or discretion in investment decisions, or as a passive investment, of less than two percent (2%) of the outstanding shares of capital
stock of any corporation with one or more classes of its capital stock listed on a national securities exchange or publicly traded on a national securities exchange or in the over-the-counter market shall not constitute a breach of this Section. For
purposes of this Agreement, “Affiliate,” means, with respect to any specific entity, any other entity that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control
with such specified entity. 
 1.6       Covenant not to
Compete.    During the term of this Agreement and for a period of one (1) year thereafter, Executive shall not engage in competition with the Company and/or any of its Affiliates, either directly or indirectly, in any
manner or capacity, in any phase of the business of developing, manufacturing and marketing of (a) products incorporating tetrahydrocannabinol (THC) or derivatives or synthetic versions thereof, (b) spray technologies for use in drug
delivery of pain medication, or (c) any new molecules which were in development at the time of departure, except with the prior written consent of the Board. 
 2.        AT-WILL EMPLOYMENT.  

Executive’s employment relationship with the Company is, and shall all times remain, at will. This means that
either Executive or the Company may terminate the employment relationship at any time, for any reason or for no reason, with or without cause or advance notice. 
 3.        COMPENSATION AND BENEFITS. 

 3.1       Salary.      The Company shall pay
Executive a base salary at the annualized rate of Two Hundred and Twenty-Five Thousand Dollars ($225,000.00) (the “Base Salary”), less payroll deductions and all required withholdings, payable in regular periodic payments in
accordance with the Company’s normal payroll practices. The Base Salary shall be prorated for any partial year of employment on the basis of a 365-day fiscal year. The Base Salary may be adjusted from time to time in the Company’s
discretion. 
 3.2     Performance Bonus.    Executive will be
eligible to participate in any officer incentive program of the Company adopted by the Board and/or the compensation committee of the Board that provides for the payment of annual performance-based cash bonuses to the Company’s executive
officers. Any cash bonus earned by Executive pursuant to any such program will be subject to standard payroll deductions and applicable tax withholdings. In order to earn and receive any such cash bonus, Executive must remain employed by the Company
as an employee in good standing through the end of the applicable calendar year and the payout date for the bonus. 

  
 2 








 3.3       Standard Company
Benefits.    Executive shall, in accordance with Company policy and the terms of the applicable plan documents, be eligible to participate in benefits under any benefit plan or arrangement that may be in effect from time to
time and made available to the Company’s employees. 
 3.4
      Expense Reimbursements.    The Company will reimburse Executive for all reasonable business expenses Executive incurs in conducting his duties hereunder, pursuant to the Company’s
usual expense reimbursement policies. 
 4.        PROPRIETARY
INFORMATION OBLIGATIONS. 
  As a condition of employment Executive
agrees to execute and abide by the Company’s Proprietary Information and Inventions Agreement (“PIIA”). Executive acknowledges and agrees that his obligations under the PIIA are retroactively effective to and including
his first day of employment with the Company. 
 5.        COMPENSATION
UPON TERMINATION. 
  5.1       Termination Without Cause or Resignation For Good Reason.    If the Company terminates Executive’s employment without Cause
(as defined below and other than as a result of Executive’s death or disability), or if Executive resigns his employment for Good Reason (as defined below), then the Company shall pay Executive any base salary and accrued and unused vacation
benefits earned through the date of termination, at the rate in effect at the time of termination, less standard deductions and withholdings. In addition, if Executive furnishes to the Company an executed waiver and release of claims in a form to be
provided by the Company (the “Release”) within the time period specified therein, but in no event later than forty-five (45) days following Executive’s termination, and if Executive allows such Release to become
effective in accordance with its terms, then Executive shall be entitled to: (1) severance in the form of continuation of Executive’s salary (at the Base Salary rate in effect at the time of termination) for a period of twelve
(12) months following the termination date; (2) an additional severance payment equal to Executive’s target bonus for the year in which the qualifying termination or resignation is effective, pro rated for the number of days Executive
was employed by the Company in such year; and (3) accelerated vesting of any unvested shares subject to any outstanding stock options and/or other equity awards, such that, on the effective date of the Release, the Executive shall be vested in
one hundred percent (100%) of the shares subject to such options and/or awards. The severance payments will be subject to standard payroll deductions and withholdings and will be made on the Company’s regular payroll cycle, provided,
however, that any payments otherwise scheduled to be made prior to the effective date of the Release shall accrue and be paid in a lump sum on the first payroll period that follows such effective date. 

 5.2       Termination Other Than Without Cause or
Resignation Other Than For Good Reason.    If Executive’s employment with the Company ends for any reason or in any circumstance other than those specified in Section 5.1 above, including
but not limited to a termination by the Company for Cause or a resignation by Executive without Good Reason, the Company shall pay Executive any base salary and accrued and unused vacation benefits earned through the date of termination, at the rate
in effect at the time of termination, less standard deductions and withholdings. The Company shall thereafter have no further obligations to Executive under this Agreement, except as otherwise provided by law. 

  
 3 








 6.       DEFINITIONS. 

For purposes of this Agreement, the following terms shall have the following meanings: 

6.1       Cause.    “Cause” shall mean
the occurrence of any of the following, as determined by the Board: (i) Executive’s conviction of any felony or any crime involving fraud or dishonesty; (ii) Executive’s participation (whether by affirmative act or omission) in a
fraud, act of dishonesty or other act of misconduct against the Company and/or its affiliates; (iii) conduct by Executive which, based upon a good faith and reasonable factual investigation by the Board, demonstrates Executive’s gross
unfitness to serve; (iv) Executive’s violation of any statutory or fiduciary duty, or duty of loyalty, owed to the Company; (v) Executive’s breach of any material term of any material contract between such Executive and the
Company, after written notice to Executive and an opportunity of at least thirty (30) days to cure; (vi) Executive’s repeated violation of any material Company policy, after written notice to Executive and an opportunity of at least
thirty (30) days to cure; and/or (vii) Executive’s repeated failure to adequately perform his job duties, after written notice to Executive and an opportunity of at least thirty (30) days to cure. Whether a termination is for
Cause shall be decided by the Board in its sole and exclusive judgment and discretion. 
 6.2
      Good Reason.    “Good Reason” for Executive to terminate his employment hereunder shall mean the occurrence of any of the following events without Executive’s
consent: (i) a material reduction by the Company of Executive’s Base Salary as initially set forth herein or as the same may be increased from time to time, provided, however, that if such reduction occurs in connection with a Company-wide
decrease in Executive compensation, such reduction shall not constitute Good Reason for Executive to terminate his employment; (ii) a material breach of this Agreement by the Company; (iii) a material reduction that amounts to an adverse
change in Executive’s duties, authority, or responsibilities relative to Executive’s duties, authority, or responsibilities in effect immediately prior to such reduction; or (iv) a relocation of Executive’s principal place of
employment to a location outside of the greater Phoenix metropolitan area and that constitutes a material change in the geographic location at which Executive must perform services under this Agreement. 

Provided, however, that, any such termination by Executive shall only be deemed for Good Reason pursuant to this definition
if: (1) Executive gives the Company written notice of his intent to terminate for Good Reason within thirty (30) days following the first occurrence of the condition(s) that he believes constitute(s) Good Reason, which notice shall
describe such condition(s); (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the “Cure Period”); and (3) Executive voluntarily terminates his
employment within thirty (30) days following the end of the Cure Period. 
 7.
         GENERAL PROVISIONS. 

   7.1         Representations and
Warranties.    Executive represents and warrants that Executive is not restricted or prohibited, contractually or otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and
that Executive’s execution and performance of this Agreement will not violate or breach any other agreements between the Executive and any other person or entity. 

  
 4 








  7.2        Survival.      Sections 4, 5, 6 and 7 of this Agreement will survive the termination of this Agreement. 

 
7.3
      Miscellaneous.    This Agreement, along with the PIIA, constitutes the complete, final and exclusive embodiment of the entire
agreement between Executive and the Company with regard to its subject matter. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such
promises, warranties or representations. This Agreement may not be modified or amended except in a writing signed by both Executive and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives,
successors and assigns of both Executive and the Company, and inure to the benefit of both Executive and the Company, and to his and its heirs, successors and assigns. If any provision of this Agreement is determined to be invalid or unenforceable,
in whole or in part, this determination will not affect any other provision of this Agreement and the provision in question will be modified so as to be rendered enforceable. This Agreement will be deemed to have been entered into and will be
construed and enforced in accordance with the laws of the State of Arizona as applied to contracts made and to be performed entirely within Arizona. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any
waiver of a breach of this Agreement shall be in writing and shall not be deemed to be a waiver of any successive breach. This Agreement may be executed in counterparts and facsimile signatures will suffice as original signatures. 

7.4     Section 409A.    The severance benefits and other payments
payable under this Agreement are intended to qualify for an exemption from application of Section 409A of the Internal Revenue Code of 1986, as amended and the Treasury Regulations and other guidance promulgated thereunder (the
“Code”) and any state law of similar effect (collectively “Section 409A”) or comply with its requirements to the extent necessary to avoid adverse personal tax consequences under
Section 409A, and any ambiguities herein shall be interpreted accordingly. Notwithstanding anything to the contrary herein, the following provisions apply to the extent benefits provided herein are subject to Section 409A. Severance
benefits shall not commence until Executive has a “separation from service” for purposes of Section 409A. Each installment of severance benefits is a separate “payment” for purposes of Treas. Reg.
Section 1.409A-2(b)(2)(i), and the severance benefits are intended to satisfy the exemptions from application of Section 409A provided under Treasury Regulations Sections 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9). However, if such
exemptions are not available and Executive is, upon separation from service, a “specified employee” for purposes of Section 409A, then, solely to the extent necessary to avoid adverse personal tax consequences under Section 409A,
the timing of the severance benefits payments shall be delayed until the earlier of (i) six (6) months and one day after Executive’s separation from service, or (ii) Executive’s death. 

Executive shall receive severance benefits only if Executive executes and returns to the Company, within the applicable
time period set forth therein but in no event more than forty-five (45) days following the date of separation from service, the Release, and permits such Release to become effective in accordance with its terms (such latest permitted date, the
“Release Deadline Date”). If the severance benefits are not covered by one or more exemptions from the application of Section 409A and the Release could become effective in the calendar year following the
calendar year in which Executive separates from service, the Release will not be deemed effective any earlier than the Release Deadline Date. None of the severance benefits will be paid or otherwise delivered prior to the effective date of the
Release. Except to the minimum extent that payments must be delayed because Executive is a “specified employee” or until the effectiveness of the Release, all amounts will be paid as soon as practicable in accordance with the
Company’s normal payroll practices. 

  
 5 








 7.5
      Section 280G.    If any payment or benefit Executive will or may receive from the Company or otherwise (a “280G Payment”) would (i) constitute a
“parachute payment” within the meaning of Section 280G of the Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then any such
280G Payment (a “Payment”) shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would result in no portion of the Payment (after
reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable
federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in Executive’s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all
or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction
shall occur in the manner (the “Reduction Method”) that results in the greatest economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be
reduced pro rata (the “Pro Rata Reduction Method”). 
 Notwithstanding the foregoing, if
the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction
Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows: (A) as a first priority, the modification shall preserve to the greatest extent
possible, the greatest economic benefit for Executive as determined on an after-tax basis; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before
Payments that are not contingent on future events; and (C) as a third priority, Payments that are “deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred
compensation within the meaning of Section 409A. 
 Unless Executive and the Company agree on an
alternative accounting firm or law firm, the accounting firm engaged by the Company for general tax compliance purposes as of the day prior to the effective date of the change in control transaction triggering the potential 280G Payment shall
perform the foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting such change in control transaction, the Company shall appoint a nationally
recognized accounting or law firm to make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting or law firm required to be made hereunder. The Company shall use commercially
reasonable efforts to cause the accounting or law firm engaged to make the determinations hereunder to provide its calculations, together with detailed supporting documentation, to Executive and the Company within fifteen (15) calendar days
after the date on which Executive’s right to a 280G Payment becomes reasonably likely to occur (if requested at that time by Executive or the Company) or such other time as requested by Executive or the Company. 

  
 6 








 If Executive receives a Payment for which the Reduced Amount was determined
pursuant to the first paragraph of this Section 7.5 and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, Executive agrees to promptly return to the Company a sufficient amount of
the Payment (after reduction pursuant to clause (x) of the first paragraph of this Section 7.5) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined
pursuant to clause (y) of the first paragraph of this Section 7.5, Executive shall have no obligation to return any portion of the Payment pursuant to the preceding sentence. 

[SIGNATURE PAGE TO FOLLOW] 

  
 7 








 IN WITNESS
WHEREOF,    the parties have executed this Amended and Restated Employment Agreement as of the day and year first written above. 

 

			
	INSYS THERAPEUTICS, INC.
		
	By:	 	 /s/ Michael Babich

		 	Name: Michael Babich
		 	Title: President and Chief Executive Officer


  

	
	Accepted and agreed:
	
	 /s/ Larry Dillaha

	Dr. Larry Dillaha


  
 8